TILT Biotherapeutics

company

About

TILT Biotherapeutics Ltd is the leading company globally working in the area of enabling tumor.

  • 1 - 10

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
€9.90M
Industries
Apps,Biotechnology,Health Care
Founded date
Jan 1, 2013
Number Of Employee
1 - 10
Operating Status
Active

TILT Biotherapeutics is the leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. TILT is a preclinical stage company working in the field of cancer immunotherapy and will soon translate its unique approach into clinical trials. The company’s patented technology involves utilization of oncolytic viruses for enhancement of tumor T-cell therapy. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR-T therapy of solid tumors as currently achieved for CD19+ hematological tumors.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
€22M
TILT Biotherapeutics has raised a total of €22M in funding over 2 rounds. Their latest funding was raised on Feb 7, 2023 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 7, 2023 Series Unknown €9.90M 2 European Innovation Council Detail
Feb 7, 2023 Grant €2.10M 1 European Innovation Council Detail
Dec 14, 2016 Seed €10M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
3
TILT Biotherapeutics is funded by 3 investors. European Innovation Council and ACME Investments are the most recent investors.
Investor Name Lead Investor Funding Round
European Innovation Council Yes Series Unknown
ACME Investments Series Unknown
Keksintösäätiö Seed